F-star Biotechnology

F-star is a clinical-stage biopharmaceutical company developing bispecific antibody immuno-oncology products selected for their potential to transform the treatment of cancer. Through the application of its highly efficient Modular Antibody Technology™ platform, F-star is the only biotechnology company able to create bispecific antibodies, where the second binding site is in the constant Fc region of an antibody, offering unprecedented ease in the discovery, development and manufacturing of bispecific antibody products. The strength of the technology and programmes has been leveraged through partnerships with leading biopharmaceutical companies including, AbbVie, Bristol-Myers Squibb, Merck Serono and Boehringer Ingelheim.
Company Growth (employees)
Type
Private
HQ
Cambridgeshire, GB
Founded
2006
Size (employees)
67 (est)+7%
Website
f-star.com
F-star Biotechnology was founded in 2006 and is headquartered in Cambridgeshire, GB

Key People at F-star Biotechnology

John Haurum

John Haurum

CEO
Eugen Stermetz

Eugen Stermetz

CFO
Jane Dancer

Jane Dancer

coo

F-star Biotechnology Office Locations

F-star Biotechnology has offices in Cambridgeshire and Wien
Wien, AT
7 Schwarzenbergpl.

F-star Biotechnology Data and Metrics

Summary Metrics

Founding Date

2006

Total Funding

$57.3 m

Latest funding size

$9.4 m

Time since last funding

over 3 years

Investors

F-star Biotechnology's latest funding round in October 2013 was reported to be $9.4 m. In total, F-star Biotechnology has raised $57.3 m

F-star Biotechnology Financial Metrics

F-star Biotechnology's revenue was reported to be £7.7 m in FY, 2015 which is a 8% increase from the previous period.
Numbers are in £, GBP

Revenue (FY, 2015)

7.7 m

Revenue growth (FY, 2014 - FY, 2015), %

8%

Net income (FY, 2015)

(817.3 k)

Cash (31-Dec-2015)

1.3 m
Numbers are in £, GBPFY, 2013FY, 2014FY, 2015

Revenue

2.4 m7.1 m7.7 m

Revenue growth, %

196%8%

Pre tax profit

(3.3 m)825.7 k(797.2 k)

Net Income

(2.8 m)831.7 k(817.3 k)
Numbers are in £, GBPFY, 2013FY, 2014FY, 2015

Cash

1.2 m240.8 k1.3 m

Accounts Receivable

752.5 k65.2 k

Current Assets

2.6 m2.8 m6.1 m

PP&E

400.6 k491.7 k946.7 k

Goodwill

1.5 k255

Total Assets

3 m3.2 m7 m

Accounts Payable

872.8 k966.9 k546.3 k

Current Liabilities

3.1 m2.3 m6.5 m

Retained Earnings

(2.8 m)831.7 k(817.3 k)

Total Equity

(60.8 k)942.9 k460.8 k

Financial Leverage

-50 x3.4 x15.2 x
Numbers are in £, GBPFY, 2013FY, 2014FY, 2015

Cash From Operating Activities

(887.6 k)(211.3 k)(1.4 m)

Cash From Financing Activities

(142.6 k)(443.3 k)4.6 m

Income Taxes Paid

460.2 k6 k(20.1 k)
Y, 2015

Financial Leverage

15.2 x

F-star Biotechnology Online and Social Media Presence

F-star Biotechnology Company Life and Culture

You may also be interested in